PAVmed Inc.

PAVmed Inc. is a U.S.-based life sciences company organized around a portfolio of medical technologies developed through separate operating subsidiaries. Its business includes diagnostic and cancer-care products, with a focus on devices, tests, and related platforms for unmet clinical needs.

−30 564,8 %

−207,0 %

564,8 %

−97,6 %

0.17

0.17

— PAVmed Inc.
%
Esophageal cancer screening diagnostics55% Non-endoscopic screening and diagnostic tools for Barrett's esophagus and esophageal cancer risk.
Cancer care software/platform services25% Subscription-based cancer care platform services tied to Veris Health.
Medical device commercialization10% Development and commercialization of proprietary medical devices and related consumables.
Incubator and pipeline development10% Early-stage product development and incubation of new healthcare technologies.

PAVmed sells into the healthcare ecosystem rather than directly to consumers, with demand driven by physicians,...

  • Physicians and gastroenterology practicesprimary

    They buy or order EsoGuard and use EsoCheck-based workflows to screen at-risk patients for Barrett's esophagus.

  • Hospitals and health systemsprimary

    They support clinical deployment, patient collection, and research programs around esophageal screening and cancer care.

  • Clinical research institutionssecondary

    They participate in validation studies and grant-funded trials evaluating EsoCheck and EsoGuard.

  • Cancer care organizationssecondary

    They use Veris Health platform services for cancer care coordination and related subscription workflows.

PAVmed is headquartered in the United States and its reported operating activity is primarily U.S.-based...

  • •Headquartered and primarily operated in the United States
  • •Clinical studies and commercialization efforts are U.S.-focused
  • •Revenue is tied to U.S. healthcare providers and patients
  • •Regulatory exposure is concentrated in the U.S. FDA environment
  • •Research partnerships involve U.S. academic medical centers

PAVmed’s strategy is to build and commercialize a portfolio of novel healthcare technologies through a parent-company...

01
Commercialize EsoGuard and EsoCheckshort-term

Clinical adoption depends on evidence, physician acceptance, and workflow integration.

02
Build Veris Health subscription platformmedium-term

Recurring platform revenue can diversify the business beyond single-product diagnostics.

03
Use flexible subsidiary financingshort-term

Capital can be matched to each asset’s development stage and funding needs.

PAVmed depends on successful commercialization of a small number of healthcare assets, so adoption, reimbursement, and...

high

FDA and regulatory enforcement risk

EsoGuard is tied to laboratory-developed test assumptions and regulatory enforcement discretion.

Scope
EsoGuard and related diagnostics
Materiality
high
high

Commercial adoption risk

Revenue depends on physicians and healthcare systems adopting new screening and care tools.

Scope
EsoGuard, EsoCheck, Veris Health
Materiality
high
high

Financing and dilution risk

The company has used ATM equity sales and convertible/preferred structures to fund operations.

Scope
Common stock, preferred stock, convertible notes
Materiality
high
medium

Clinical evidence risk

Market acceptance of screening products depends on trial outcomes and published validation.

Scope
NIH-backed EsoCheck/EsoGuard study
Materiality
medium
Revenue recognition for subscription and diagnostic services
Can create quarter-to-quarter volatility in reported revenue
Fair value measurement of convertible notes and preferred stock
Can materially affect net results without corresponding cash flow
Debt extinguishment accounting
Can distort period-to-period comparability
Equity issuance and dilution
Important for investors modeling ownership dilution

PRECIGEN, INC.

PGEN · Pharmaceutical Preparations

RenovoRx, Inc.

RNXT · Pharmaceutical Preparations

Advanced Biomed Inc.

ADVB · Services-Medical Laboratories

Evofem Biosciences, Inc.

EVFM · Pharmaceutical Preparations

VERU INC.

VERU · Pharmaceutical Preparations

P3 Health Partners Inc.

PIII · Services-Health Services

: 29/04/2026